Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703528 | 1.00 | NOS1 (0.48) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL5643032 | 0.99 | NOS3 (0.48) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL5643026 | 0.99 | NOS3 (0.48) | NOS1NOS3NOS2 | |
| SCHEMBL4700803 | 0.88 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL4700799 | 0.88 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL5640589 | 0.87 | NOS1 (0.45) | NOS1NOS3NOS2 | |
| SCHEMBL4700287 | 0.86 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL4700283 | 0.86 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL4702008 | 0.85 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL4702018 | 0.85 | NOS1 (0.46) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | claimed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | claimed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | claimed |
| EP-1527068-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-04 | — | — | EP | claimed |
| WO-2004011402-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-02-05 | — | — | WO | claimed |
| EP-1527068-B1 | NOVEL ARYLIMIDAZOLE DERIVATIVES, THEIR USE AS NO-SYNTASE INHIBITORS AND AS MODULATORS OF SODIUM CHANNELS | SOD CONSEILS RECH APPLIC (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7192975-B2 | Arylimidazole derivatives, preparation and therapeutic used thereof | SOCIETE DE CONSEILS DE RECHERCHES ET D''APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-20 | — | — | US | disclosed |
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | IPSEN PHARMA S.A.S. (FR) | 2005-10-20 | — | — | US | disclosed |
| EP-1527068-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-04 | — | — | EP | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| WO-2004011402-A2 | NOVEL ARYLIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234118-A1 | Novel aryllimidazole derivatives, preparation and therapeutic used thereof | OPRL1, CBR3, SCN5A | NOS1 680/4885NOS3 207/4885NOS2 501/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | NOS1 1143/4885NOS3 798/4885NOS2 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.